Key result
Restarting oral anticoagulation in prosthetic heart valve patients after intracranial hemorrhage resulted in 1 recurrent bleed (7.7%) and 3 cerebral embolic events (23.1%) over 23.5 months.
Why the study?
Does restarting oral anticoagulation cause recurrent bleeding or prevent thromboembolism in patients with prosthetic heart valves after intracranial hemorrhage?
Cohort (n=35)
Does restarting oral anticoagulation cause recurrent bleeding or prevent thromboembolism in patients with prosthetic heart valves after intracranial hemorrhage?
Temporary cessation of oral anticoagulation in prosthetic heart valve patients with intracranial hemorrhage appears safe, with a low risk of recurrent bleeding upon restarting.
No takes yet. Share an insight, caveat, or question.
Suggests restarting OAC after intracranial hemorrhage may carry low recurrent bleeding risk but persistent em.
Butler et al. (1998) conducted a cohort in Oral anticoagulant-related intracranial or intraspinal haemorrhage (n=35). Restarting oral anticoagulation (OAC) was evaluated on Recurrent bleeding and thromboembolism. Restarting oral anticoagulation in prosthetic heart valve patients after intracranial hemorrhage resulted in 1 recurrent bleed (7.7%) and 3 cerebral embolic events (23.1%) over 23.5 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: